Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16).

MLA

Han, Hye Sook, et al. “Ramucirumab plus Paclitaxel as Second-Line Treatment in Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: A Nationwide Real-World Outcomes in Korea Study (KCSG-ST19-16).” Therapeutic Advances in Medical Oncology, vol. 13, Sept. 2021, p. 17588359211042812. EBSCOhost, https://doi.org/10.1177/17588359211042812.

APA

Han, H. S., Kim, B. J., Jee, H.-J., Ryu, M.-H., Park, S. H., Rha, S. Y., Kim, J. G., Bae, W. K., Lee, K.-W., Oh, D.-Y., Kim, I.-H., Sym, S. J., Oh, S. Y., Kim, H. S., Byun, J.-H., Kim, D. S., Suh, Y. J., An, H., & Zang, D. Y. (2021). Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16). Therapeutic Advances in Medical Oncology, 13, 17588359211042812. https://doi.org/10.1177/17588359211042812

Chicago

Han, Hye Sook, Bum Jun Kim, Hee-Jung Jee, Min-Hee Ryu, Se Hoon Park, Sun Young Rha, Jong Gwang Kim, et al. 2021. “Ramucirumab plus Paclitaxel as Second-Line Treatment in Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: A Nationwide Real-World Outcomes in Korea Study (KCSG-ST19-16).” Therapeutic Advances in Medical Oncology 13 (September): 17588359211042812. doi:10.1177/17588359211042812.